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1569-1993/© 201A cocktail drug therapy for patients with cystic ﬁbrosis?1 Vertex press release (24 June, 2014): “Two 24-week phase 3 studies of
lumacaftor in combination with ivacaftor met primary endpoint with statistically
signiﬁcant improvements in lung function (FEV1) in people with cystic ﬁbrosisMultiple mutations in the gene encoding the cystic fibrosis
transmembrane conductance regulator (CFTR), an epithelial anion
channel, disrupt its normal function, cause a variety of epithelial
disorders and lead to the life-shortening disease cystic fibrosis
(CF). Current therapies for CF target disease symptoms. However,
directly restoring activity to mutant CFTR is expected to further
alleviate disease complications in patients with CF leading to
improve quality of life and life expectancy. The recent discovery of
new drugs that enhance CFTR plasma membrane expression
(correctors) and channel activity (potentiators) provides a promis-
ing drug therapy for CF. Ivacaftor (VX-770), a CFTR potentiator
approved by the US Food and Drug Administration (FDA) and the
European Medicines Agency (EMA) for patients with CF aged
6 years and older carrying the G551D mutation, shows significant
improvement to patients' lung function, elevating the predicted
forced expiratory volume in 1 second (FEV1) by about 10% and
reducing the time to first pulmonary exacerbation by about 50%
[10]. More recently, VX-770 has been approved by the FDA
(NDA 203188, www.fda.gov) and recommended by the EMA
(EMA/CHMP/365663/2014) for use with an additional eight CF
gating (class III) mutations (G178R, S549N, S549R, G551S,
G1244E, S1251N, S1255P and G1349D), although, including
G551D, these mutations still just occur in ~5% of CF patients
worldwide.
In this issue of the JCF, Kopeikin et al. [6] use the
patch-clamp technique, the gold standard method for functional
studies of ion channels, to measure the direct effects of drugs on
the activity of the CFTR channel. Consistent with previous
studies [12,13], the authors found that VX-770 was able to
stimulate the most common CF mutant, F508del-CFTR,
occurring in ~90% of CF patients and also known to have a
gating defect (class III) once its major trafficking (class II)
defect is rescued. This finding will likely greatly enlarge the
drug market for VX-770. Moreover, the data suggest that
VX-770 could be a prospective chemical template to develop a
universal CFTR potentiator for treating patients with any CFTR
gating mutation that reduces channel activity.
To understand the pharmacologic mechanisms how VX-770
potentiates CFTR activity, Kopeikin et al. [6] found that this
potentiator stimulated the ATP-dependent channel activity of
F508del-CFTR by increasing both the frequency and the durationl article: http://dx.doi.org/10.1016/j.jcf.2014.04.003.
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shows that CFTR gating by VX-770 was not strongly
ATP-dependent. First, the ATP analogue P-dATP, a powerful
stimulator of ATP-dependent channel gating, had marginal effect
on F508del-CFTR following the action of VX-770 [6]. Second,
the mutation E1371S, which greatly stimulates channel activity
by preventing ATP hydrolysis-mediated channel closure, had
modest effects on the action of VX-770 [6]. These data suggest
that the VX-770-binding site may not be near the ATP binding
pockets of CFTR [11]. Identifying the binding site of VX-770 in
CFTR should provide crucial information to guide new drug
development.
Because the F508del mutation reduces both the protein cell
surface expression (class II) and channel activity of CFTR (class
III), a cocktail of drugs combining a corrector to increase protein
plasma membrane levels such as the experimental drug VX-809,
also known as lumacaftor [13] and a potentiator to enhance channel
activity such as VX-770 [6,12,13] may form an ideal strategy to
improve F508del-CFTR activity in the cell membrane. Consistent
with this idea, VX-809-treated cells have markedly increased cell
surface expression of F508del-CFTR, possibly by directly
interacting with CFTR's cytoplasmic domains including
nucleotide-binding domain 1 and the intracellular loops of the
membrane-spanning domains [4,5,8]. The present work [6]
demonstrates that although VX-809 could not directly activate
CFTR channels, at 37 °C this experimental drug delivered
significant numbers of channels to the cell surface that were
activated by cAMP-dependent phosphorylation and further
stimulated by ATP agonists or VX-770. Together the data argue
that the combination of different correctors and potentiators (i.e.
cocktail drug therapy) is likely to be a promising treatment for
patients with CF and the F508del mutation [1]. This idea is
reinforced by a recent phase 2 clinical trial that showed significant
improvements in FEV1 in CF patients during the period of
treatment with a combination of VX-809 and VX-770 [2] and is
further emphasized by the results of the phase 3 combo trial,
despite the modest FEV1 improvement reported
1.who have two copies of the F508del mutation” (http://investors.vrtx.com/
releasedetail.cfm?ReleaseID=856185).
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490 EditorialIt is surprising that in the current study [6], VX-809-treated
cells generated significant F508del-CFTR-mediated currents
without functional correction of channel gating. This result
contrasts with previous data [13]. However, the present results
support earlier findings [3], suggesting that the protein
processing and channel gating defects of F508del-CFTR may
result from different mechanisms. Thus, it seems appropriate to
expect that different drugs would be required to rescue the
individual defects of F508del-CFTR [1]. In the longer term, a
multi-functional drug possibly with fewer side effects than a
cocktail, is the ultimate goal in CF drug discovery.
A concern is that both the CFTR potentiator VX-770 and the
corrector VX-809 may not be sufficient to restore all functional
defects caused by the F508del mutation [1]. Indeed, this mutant
also makes CFTR insensitive to cAMP stimulation [9] and less
stable in the cell membrane [7]. It will be interesting to know
whether this cocktail combination is beneficial to these defects.
Moreover, simply activating CFTR activity without restoring
physiological processes in epithelial tissues may not produce
long-term benefits for CF patients. Finding new drugs with low
toxicity suitable for young children and infants with CF is
essential because other secondary disease complications like
inflammation, tissue remodeling and fibrosis may occur, causing
permanent tissue damage and preventing restoration of CFTR
activity from curing CF disease. Nevertheless, the cocktail
therapy combining VX-809 and VX-770 shows scientists and
patients with CF a bright light after 25 years of cloudy skies.
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